Adding SBRT to systemic therapy could boost outcomes for some locally advanced hepatocellular carcinoma patients

Published Date: 25 Dec 2024

Recent results from the Phase III NRG-RTOG 1112 clinical study showed that the addition of stereotactic body radiotherapy (SBRT) to systemic therapy with sorafenib significantly improved progression-free survival (PFS) and ...

Read Full News

Latest News

Nonpharmacologics May Reduce Anxiety, Depression in SUD

Neuromodulation, mind-body therapy, and other nonpharmacologic interventions are linked to improved psychiatric symptoms in people with SUD, a meta-analysis shows.

WHO Warns Loosely Regulated Nicotine Pouches Risk Youth Addiction

The World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning ⁠that the highly addictive products were being...

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents

Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk

Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk

Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy

Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Latest News

Neuromodulation, mind-body therapy, and other nonpharmacologic interventions are linked to improved psychiatric symptoms in people with SUD, a meta-analysis shows.

The World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning ⁠that the highly addictive products were being...

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents

Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk

Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy

News All Time

SCOTUS Grapples With Multibillion-Dollar Lawsuits Over Roundup Cancer Claims

Several justices seemed sympathetic to Monsanto's argument that it can't be sued under state law

Rectal Cancer 'Crisis'; Smells Like Cancer; Flushing Away Clues to Colon Cancer

News, features, and commentary about cancer-related issues

Lung Cancer Screening Rates in Eligible Adults Remain Low, Uneven

However, rates were improved from previous survey results

FDA Says First 'Real-Time' Clinical Trial Is Underway

Two sponsors are on board, with a larger pilot program planned later this year

Novel Mimetic Bispecific Antibody Superior to Standard Care in Hemophilia A

Mim8 prophylaxis significantly reduced bleeding events in patients with or without inhibitors

High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy

Three-fourths of patients had cancer-free mediastinal lymph nodes, clear surgical margins in 93%

Pooled Cord Blood Transplants Achieve Near-Perfect Results in Early Trial

Disease-free survival of 96% with no severe GVHD in acute leukemia, other blood cancers

FDA Panel Endorses Capivasertib Use in Prostate Cancer

Agency staff expressed uncertainty over whether PFS benefit was "clinically meaningful"

Paging Dr. AI; Myth Busting in Cancer; Oncologists Shine in Malpractice Survey

News, features, and commentary about cancer-related issues

J. Craig Venter, Who Won the Race to Sequence the Human Genome, Dies at 79

His death followed a hospitalization for cancer treatment side effects

I Was Told I Had 6 Months to Live. That Was 20 Years Ago.

Here's what two brain surgeries taught me about public health and care access

Woman Loses 6-Year Battle With Mouth Tumor

Rare ameloblastoma rapidly recurs and metastasizes despite numerous radical excisions

Why Did Rare Cancer Shrink on Its Own?

Case illustrates the mystery of spontaneous regression

What Caused a Man to Develop Friable Bleeding Nodules on His Arms and Hips?

The cause lies in a lengthy history of cancer treatment, confirmed by histopathology analysis

Oncologist on Hantavirus Cruise; Bile Duct Cancer Drug OK'd; Untreated Lung Cancers

News, features, and commentary about cancer-related issues

Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth

Deaths directly attributed to vitamin K deficiency bleeding have started to climb in recent years

Recommended News For You

Shorter, less intense regimen still effective for HPV-linked throat cancer, study shows

Adopted cancer cells and the effects of their presence.

Combo Therapy Boosts Early CML Response but Not Long Term

Pickleball program boosts health and wellness for cancer survivors, study finds

Sustained reduction found in prostate cancer mortality with prostate-specific antigen screening

"We Caught It Early": Advantage or Disadvantage?

From 40 to 74, the US Preventive Services Task Force advises every two years for screening mammography.

Recommended Articles For You

Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025 

Everything You Need To Know About Melanoma Choroid: Causes, Symptoms, and Treatment 

Uncovering the Hidden Picture: Using Ultrasound to Diagnose Breast Cancer 

The Significance of APTT Blood Test Results for Detecting Coagulation Disorders 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

2.

FDA approves Blenrep for relapsed or refractory multiple myeloma

3.

X-ray and radar technology combined to reduce cancer screening risks

4.

Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.

5.

Researchers discuss HER2-low and HER2-zero in breast cancer

1.

Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options

2.

Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment

3.

The New Era of Oncology: Key Updates and Clinical Insights

4.

HIPEC in Platinum-Sensitive Ovarian Cancer: A Promising Yet Controversial Option

5.

Theranostics and Radioligand Therapy: Precision Cancer Care with Targeted Radionuclides

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial

2.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I

3.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II

5.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot